During the 68-week experiment, those who got Semaglutide/L-Carnitine lost an average of 15% of their starting weight, or roughly 33 pounds
This reduced motility is medically termed delayed gastric emptying or gastric stasis
World J Hepatol
To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
But all drugs have their risks, and GLP-1s are no exception